July 10, 2025: Laurus Labs share price, a key player in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently trades at ₹791.4. The stock experienced intraday fluctuations, hitting a low of ₹786.75 and a high of ₹799.4. Over the past 52 weeks, the share price has ranged between ₹390.3 and ₹797.9, reflecting significant growth.
In terms of recent performance, Laurus Labs recorded a slight dip of -0.26% over the last trading day. However, it showed robust gains over longer periods, rising 18.84% over the past month and an impressive 30.62% in the last three months.
Technical analysis indicates the daily pivot level at ₹793.05, with resistance levels at ₹799.35 (R1), ₹805.7 (R2), and ₹812 (R3). Support levels are marked at ₹786.7 (S1), ₹780.4 (S2), and ₹774.05 (S3), providing key reference points for traders.
Looking at moving averages, the 5-day Simple Moving Average (SMA) stands at ₹722.15, and the Exponential Moving Average (EMA) is at ₹774.89. For 10 days, the SMA is ₹691.35 with an EMA of ₹752.02. The 20-day averages show an SMA of ₹677.15 and EMA of ₹718.87, while the 50-day SMA and EMA are ₹636.38 and ₹670.51 respectively. Over the longer term, the 100-day SMA is ₹612.24 with EMA at ₹633.44, and the 200-day SMA and EMA stand at ₹569.84 and ₹586.25.
When compared to its competitors within the pharma sector, Laurus Labs has demonstrated superior performance. Over the past week, the stock gained 4.77%, 19.22% in the last month, and 31.04% in three months. Its six-month, one-year, three-year, and five-year returns stand at 36.12%, 68.1%, 61.51%, and a remarkable 564.59%, respectively.
In contrast, Sun Pharmaceutical Industries, another major player, has faced challenges with a weekly loss of 1.15%, a monthly decline of 1.71%, and a three-month drop of 1.67%. However, its long-term returns over three and five years are 93.68% and 236.3%, respectively.
Overall, Laurus Labs shows strong momentum and resilience in the Pharmaceuticals sector, making it an attractive stock for investors eyeing midcap pharma opportunities.